Inaktiver Wert

Ocata Therapeutics Inc Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries	10.02.16
Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics	22.01.16
Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells	28.12.15
Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis	03.12.15
OCATA THERAPEUTICS : Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.	11.11.15

Manager	Titel	Alter	Seit
Yoshitsuga Shitaka PSD	President	-	-
John Heffernan PRN	Corporate Officer/Principal	-	03.02.15

Aufsichtsräte	Titel	Alter	Seit
Percival Barretto-Ko BRD	Director/Board Member	51	-
Masaaki Hirano BRD	Director/Board Member	57	-
Toru Yoshimitsu BRD	Director/Board Member	61	-

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 Mrd.
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 Mrd.
ARGENX SE	+1,69 %	22,15 Mrd.
BIONTECH SE	-17,37 %	21,02 Mrd.
GENMAB A/S	-9,30 %	18,15 Mrd.
WUXI APPTEC CO., LTD.	-41,01 %	16,74 Mrd.
BEIGENE, LTD.	-14,85 %	16,05 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 Mrd.
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 Mrd.